Showing 11,681 - 11,700 results of 54,816 for search '(( 5 ((we decrease) OR (mean decrease)) ) OR ( 50 ((nn decrease) OR (teer decrease)) ))', query time: 0.96s Refine Results
  1. 11681
  2. 11682

    Image_5_Xylanase VmXyl2 is involved in the pathogenicity of Valsa mali by regulating xylanase activity and inducing cell necrosis.tif by Xinyue Cui (6291014)

    Published 2024
    “…In addition, we found that VmXyl2 induces plant cell necrosis regardless of its xylanase activity, whereas promoting the infection of V. mali in apple tissues. …”
  3. 11683
  4. 11684

    Reversal of conditioning-induced increases in surface expression of GluR1 and GluR2 is mediated by mGluR5. by Sheng-Chun Mao (392524)

    Published 2013
    “…<p>(A) Representative blots and mean ± SEM of GluR1 (left) and GluR2 (right) immunoreactivities from rats that had been conditioned with 10 light-shock pairings and 24 h later received 2–6 sessions of 15 presentations of light-alone trials. …”
  5. 11685
  6. 11686
  7. 11687

    Visual stimuli. by Susana Martinez-Conde (389218)

    Published 2019
    “…These responses were measured along the fold and also at the 50% luminance (i.e. the midpoint on the fold) locations in the 0.5x0.5 DVA ROIs denoted by the small white square frames flanked by white arrows. …”
  8. 11688

    Table 1_Cannabidiol reduces synaptic strength and neuronal firing in layer V pyramidal neurons of the human cortex with drug-resistant epilepsy.docx by Vladimir A. Martinez-Rojas (21758372)

    Published 2025
    “…Although multiple studies have described that CBD reduces neuronal hyperexcitability, the mechanistic basis of CBD remains a topic of ongoing research. In this study, we provide an electrophysiological portrayal of CBD’s effects on the glutamatergic transmission and intrinsic excitability of layer V pyramidal neurons of the human neocortex resected from drug-resistant epilepsy patients. …”
  9. 11689
  10. 11690
  11. 11691
  12. 11692

    Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study by Asita Wongprikorn (2837378)

    Published 2016
    “…At 12 weeks of treatment with pitavastatin compared to placebo; mean [95% confidence interval (CI)] total cholesterol (TC) was 207 (187.3, 226.8) mg/dL vs 246.3 (226.5, 266) mg/dL (<i>p</i> <0.001); mean (95% CI) triglyceride (TG) was 351.3 (193.2, 509.4) mg/dL vs 279.1 (121, 437.2) mg/dL (<i>p</i> = 0.269); mean (95% CI) high density lipoprotein (HDL) was 45.3 (40.4, 50.2) mg/dL vs 44.2 (39.3, 49.1) mg/dL (<i>p</i> = 0.354); and mean (95% CI) low density lipoprotein (LDL) was 113.2 (100.4, 126) mg/dL vs 145.6 (132.8, 158.4) mg/dL (<i>p</i> <0.001). …”
  13. 11693
  14. 11694
  15. 11695
  16. 11696
  17. 11697

    Fig 6 - by Raheleh Farahzadi (3860311)

    Published 2017
    “…Meanwhile, the treated of hADSCs for 48 hours in the presence of 1.5 × 10<sup>−8</sup> and 2.99 × 10<sup>−10</sup> M ZnSO<sub>4</sub> cause a decrease in the number of stained cells (**P < 0.01 and *** P < 0.001 compared with control group). …”
  18. 11698
  19. 11699
  20. 11700